title: Structure activity relationship of antiproliferative agents using multiple linear regression.
abstract: With cancer-related fatalities being the second leading cause of death in the USA, understanding the activity of effective chemotherapeutic agents is critical to addressing prostate and other cancers. Celecoxib, an FDA-approved drug for the treatment of colon tumors, has been used successfully as a lead compound in the development of antiproliferative agents. The ability of celecoxib to inhibit the development and progression of tumors has been connected to a number of mechanisms of actions that are both dependent on and independent of its cyclooxygenase-2 activity. A structure-based approach has been employed to develop a model that underscores the structural significance of celecoxib as an antiproliferative agent. By evaluating the structure activity of this library of molecules, we were able to create a QSAR model for predicting the antiproliferative activity of structurally similar molecules. The development of the model will be presented in this paper.
authors.affiliation: Spelman College, Atlanta, GA 30314, USA. lwinfield@spelman.edu
authors.forename: Leyte L
authors.initials: LL
authors.lastname: Winfield
authors.forename: Tasha R
authors.initials: TR
authors.lastname: Inniss
authors.forename: Dayle M
authors.initials: DM
authors.lastname: Smith
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000737:chemistry*; D000068579:Celecoxib; D003110:Colonic Neoplasms / Q000188:drug therapy; D051546:Cyclooxygenase 2 / Q000737:chemistry / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000737:chemistry; D016014:Linear Models; D011720:Pyrazoles / Q000737:chemistry*; D021281:Quantitative Structure-Activity Relationship; D013449:Sulfonamides / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; D000068579:Celecoxib